EORTC Quality of Life Questionnaire - Multiple Myeloma Module (EORTC QLQ-MY20)

EORTC Quality of Life Group


Basic description

  • Developed in 1999
  • An Item Library was created and offer the possibility to add items from other module(s)

EORTC: European Organization for Research and Treatment of Cancer


EORTC Quality of Life Group

© Copyright 1999 EORTC Study Group on Quality of Life. All rights reserved.
To be used in conjunction with the EORTC QLQ-C30 for assessing health-related quality of life in patients with multiple myeloma
Therapeutic area
  • Cardiovascular Diseases
  • Neoplasms
  • Hemic and Lymphatic Diseases
  • Immune System Diseases
  • Rare disease (Orphanet definition)
Therapeutic indication

Multiple Myeloma For more information on this rare disease, please consult the following link: Orphanet page

Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English
67 translation(s)
Bibliographic reference(s) of the original questionnaire

Stead ML, Brown JM, Velikova G, Kaasa S, Wisløff F, Child JA, Hippe E, Hjorth  M, Sezer O, Selby P. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol. 1999 Mar;104(3):605-11 (PubMed Abstract)

Cocks K, Cohen D, Wisløff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A, Graham L, Phillips A, Stead M, Velikova G, Brown J; EORTC Quality of Life Group. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007 Jul;43(11):1670-8 (PubMed Abstract)

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us